Nasdaq: NEUP

Neuphoria Therapeutics Inc. (NEUP)

Neuphoria Therapeutics Inc. is a public company that reports to the U.S. Securities and Exchange Commission and trades on Nasdaq under the ticker NEUP. Bright Analyst brings its financial statements, SEC filings, stock performance, news and peer comparisons together in one place, with AI analysis throughout.

Key facts

Ticker symbol
NEUP
Exchange
Nasdaq
SEC CIK
1191070
Official filings
SEC EDGAR

Research NEUP

  • Profile — Business description, headquarters, subsidiaries and corporate identifiers.
  • Financials — Income statement, balance sheet and cash flow from 10-K and 10-Q filings.
  • SEC Filings — Every 10-K, 10-Q and 8-K, readable inline with AI analysis.
  • Stock Analysis — Price chart, returns, technical indicators and related companies.
  • News — Latest headlines and press coverage.
  • Material Contracts — Material agreements filed as exhibits to SEC reports.
  • Benchmark — Stock performance against the S&P 500, Nasdaq-100 and Dow (through SPY, QQQ and DIA) and economic indicators.
  • Peer Comparison — Side-by-side financial ratios against industry peers.

Frequently asked questions

What is Neuphoria Therapeutics Inc.'s stock ticker?

Neuphoria Therapeutics Inc. trades under the ticker symbol NEUP on Nasdaq. Its SEC Central Index Key (CIK) is 1191070.

Where can I read Neuphoria Therapeutics Inc.'s SEC filings?

The NEUP SEC Filings page lists the 10-K annual reports, 10-Q quarterly reports and 8-K current reports Neuphoria Therapeutics Inc. has filed, with AI analysis. The original documents are also on SEC EDGAR.

How can I analyze NEUP's financial statements?

The NEUP Financials page shows Neuphoria Therapeutics Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly, taken from its XBRL filings, with an AI analysis of each statement.

How does NEUP compare with its peers and the market?

The NEUP Peer Comparison page lines Neuphoria Therapeutics Inc. up against industry peers on valuation, growth and profitability ratios, and the Benchmark page compares its stock with the S&P 500, the Nasdaq-100 and the Dow.

For information only — not investment advice.